# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Oren Livnat reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy and maintains $6 pr...
Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate...
The company announced a CEO succession plan effective August 1, 2024, under which Paul R. Edick will be retiring from his day-t...
HC Wainwright & Co. analyst Oren Livnat reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy and maintains $6 pr...